» Articles » PMID: 12630753

Rapid Clinical Progression to Diagnosis Among African-American Men with Systemic Lupus Erythematosus

Overview
Journal Lupus
Publisher Sage Publications
Specialty Rheumatology
Date 2003 Mar 13
PMID 12630753
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The initial clinical course of systemic lupus erythematosus (SLE) is variable, ranging from relatively minor manifestations progressing over years to rapid onset of fulminate disease. We sought to identify factors associated with the rapid manifestation of SLE. Chart review of military medical records was used to identify 130 patients who met the American College of Rheumatology classification criteria for SLE. Demographics, clinical criteria date of occurrence, and the date of SLE classification (at least four clinical criteria) met were documented. Prospectively stored serum samples prior to the diagnosis were evaluated for SLE autoantibodies. Median time from the first recorded criteria to diagnosis was significantly shorter in African-American (AA) males compared with AA females and European American (EA) females and males combined. AA males were more likely to have nephritis as their first clinical symptom. Also, less time transpired between the first clinical criterion and SLE diagnosis in AA males with nephritis than in other groups presenting with nephritis. Even when cases presenting with nephritis were excluded, a diagnosis of SLE was made more rapidly in AA males. African-American men progress from initial clinical manifestations to SLE diagnosis more rapidly than other ethnic or gender groups.

Citing Articles

The vascular endothelial growth factor as a candidate biomarker of systemic lupus erythematosus: a GRADE-assessed systematic review and meta-analysis.

Mangoni A, Zinellu A Clin Exp Med. 2024; 24(1):218.

PMID: 39259392 PMC: 11390800. DOI: 10.1007/s10238-024-01487-w.


Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development.

Choi M, Costenbader K Front Immunol. 2022; 13:890522.

PMID: 35720390 PMC: 9203849. DOI: 10.3389/fimmu.2022.890522.


Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner.

Gergianaki I, Bertsias G Front Med (Lausanne). 2018; 5:161.

PMID: 29896474 PMC: 5986957. DOI: 10.3389/fmed.2018.00161.


Fever of unknown origin in a male patient with systemic lupus erythematosus.

Bandara Basnayake D, Kannangara T, Welagedara L, Bandara V, Herath J Caspian J Intern Med. 2017; 8(3):217-219.

PMID: 28932375 PMC: 5596194. DOI: 10.22088/cjim.8.3.217.


Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses.

Ren J, Liao X, Vieson M, Chen M, Scott R, Kazmierczak J Clin Exp Immunol. 2017; 191(1):19-31.

PMID: 28876451 PMC: 5721231. DOI: 10.1111/cei.13046.